Maryland State Retirement & Pension System Sells 360 Shares of DaVita Inc. (NYSE:DVA)

Maryland State Retirement & Pension System trimmed its holdings in shares of DaVita Inc. (NYSE:DVA) by 12.5% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 2,517 shares of the company’s stock after selling 360 shares during the quarter. Maryland State Retirement & Pension System’s holdings in DaVita were worth $376,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of DVA. Boston Partners lifted its stake in shares of DaVita by 48.9% in the 4th quarter. Boston Partners now owns 89,453 shares of the company’s stock valued at $13,387,000 after purchasing an additional 29,394 shares during the period. Intech Investment Management LLC lifted its stake in DaVita by 1.2% in the fourth quarter. Intech Investment Management LLC now owns 27,265 shares of the company’s stock valued at $4,077,000 after buying an additional 328 shares during the period. Advisors Asset Management Inc. grew its position in shares of DaVita by 24.6% during the 4th quarter. Advisors Asset Management Inc. now owns 22,686 shares of the company’s stock worth $3,393,000 after buying an additional 4,485 shares during the period. Cibc World Markets Corp increased its stake in shares of DaVita by 8.6% in the 4th quarter. Cibc World Markets Corp now owns 7,194 shares of the company’s stock valued at $1,076,000 after acquiring an additional 571 shares during the last quarter. Finally, Catalyst Funds Management Pty Ltd raised its position in shares of DaVita by 77.8% in the 4th quarter. Catalyst Funds Management Pty Ltd now owns 4,800 shares of the company’s stock valued at $718,000 after acquiring an additional 2,100 shares during the period. 90.12% of the stock is currently owned by institutional investors and hedge funds.

DaVita Stock Up 0.1 %

DVA stock opened at $150.60 on Wednesday. The business has a 50-day moving average of $158.18 and a 200-day moving average of $157.57. DaVita Inc. has a fifty-two week low of $125.64 and a fifty-two week high of $179.60. The stock has a market capitalization of $12.05 billion, a P/E ratio of 14.02, a P/E/G ratio of 1.07 and a beta of 0.99. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.26 and a quick ratio of 1.21.

DaVita (NYSE:DVA) last issued its quarterly earnings results on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, topping the consensus estimate of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. On average, sell-side analysts anticipate that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on DVA shares. Cowen restated a “hold” rating on shares of DaVita in a report on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 target price on DaVita in a research note on Friday, February 21st. Barclays raised their price target on DaVita from $164.00 to $169.00 and gave the stock an “equal weight” rating in a research report on Tuesday, February 18th. Finally, StockNews.com lowered DaVita from a “buy” rating to a “hold” rating in a research report on Friday, March 21st. One research analyst has rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat.com, DaVita has an average rating of “Hold” and a consensus price target of $166.33.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.